A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis

19942,178 citationsJournal Article

Authors

Gilbert Bensimon · Sorbonne Université

Lucette Lacomblez · Sorbonne Université

Vincent Meininger · Hôtel-Dieu de Paris

Abstract

The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset.

Topics & Keywords

Amyotrophic Lateral Sclerosis Research Genetic Neurodegenerative Diseases Neuroscience and Neuropharmacology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 330, Issue 9, pp. 585-591

DOI: 10.1056/nejm199403033300901

Field-Weighted Citation Impact: 48.59